Report for Q1 2026
Filed with SSE · · 12 pages · Chinese
Chongqing Taiji Industry (Group) Co., Ltd. on 6ix
Earlier from Chongqing Taiji Industry (Group)
- Announcement on Obtaining Notice of Approval for Drug Clinical Trial for Shuangling Anti-diarrhea Granules
- Announcement on Release of Pledge and Pledge of Equity of Controlling Shareholder
- Announcement on Resolutions of the 37th Meeting of the 10th Board of Directors
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Notice on Convening the 1st Extraordinary General Meeting in 2026
Later from Chongqing Taiji Industry (Group)
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Obtaining Drug Registration Certificate for Metformin Hydrochloride and Empagliflozin Tablets (I)
- Announcement on DSC158A Tablets Obtaining Notice of Approval for Drug Clinical Trials
- Announcement on Passing of the Generic Drug Consistency Evaluation for Digoxin Injection
- Announcement on Participating in the 2025 SSE Main Board Benefit the People & Boost Consumption - Rural Revitalization Collective Online Performance Briefing
Follow Chongqing Taiji Industry (Group) into a list and get an email when it puts out news.
Follow Chongqing Taiji Industry (Group)